Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Medtronic

Now that Johnson & Johnson no longer sells consumer goods, it's poised to grow, along with sales of pharmaceuticals and medical technology. Medtronic's dominance in the medical device industry has allowed it to raise its dividend payout for 46 consecutive years.

3 Ultrareliable Dividend Stocks to Buy and Hold for Decades

Abbott Laboratories (NYSE:ABT) shares surged on Thursday after the company posted a second-quarter earnings beat driven by strong demand for its medical devices as surgery volumes increase. Its adjusted earnings per share of $1.08 topped the Street's expectation of $1.05.

Abbott Laboratories 2Q profit tops expectations driven by strong medical devices sales

Abbott Laboratories (NYSE:ABT ) Q2 2023 Earnings Conference Call July 20, 2023 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Larry Biegelsen - Wells Fargo Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Marie Thibault - BTIG Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2023 Earnings Conference Call.

Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript

Abbott Laboratories ABT reported second-quarter 2023 adjusted earnings of $1.08 per share, which topped the Zacks Consensus Estimate by 3.8%. However, the adjusted figure declined from the prior-year quarter's levels by 24.5%.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

Two of Abbott's businesses are recovering from recent setbacks, helping stoke a second-quarter beat Thursday and pushing Abbott stock higher.

Abbott Flirts With Breakout After Notching A Recovery In Not One, But Two Businesses

Abbott Laboratories NYSE: ABT is a tale of two stories. The first is its recovery from the COVID-19 boost and bubble.

Abbott Laboratories Has the Prescription for Higher Share Prices

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.43 per share a year ago.

Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates

Abbott Laboratories' stock ABT, +0.31% rose 1.6% in premarket trade Thursday, after the diagnostics and medical-device company posted earnings that were lower than a year ago but ahead of analyst estimates. The company had net income of $1.375 billion, or 78 cents a share, for the quarter, down from $2.018 billion, or $1.14 a share, in the year-earlier period.

Abbott Labs' stock up 1.6% premarket after earnings fall but still top analyst estimates

Abbott Laboratories on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices.

Abbott beats quarterly profit estimates on demand for medical devices

Sales of $10.0 billion driven by strong underlying base business performance Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 11.5 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition Continues to strengthen portfolio with new product approvals and expanded reimbursement coverage ABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023.

Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business

First Industrial Realty Trust

A recession or more rate hikes in late 2023? We contrarian dividend investors don't care!

3 Ignored Dividends Growing 66%+ (With Upside Ahead)

Intuitive Surgical

Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.

2 Medical Stocks to Buy as Earnings Approach

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Abbott (ABT) Might Surprise This Earnings Season

Elevance Health Inc

Home Depot

Intercontinental Exchange

Thermo Fisher Scientific

Tractor Supply

Toro

UnitedHealth Group

Visa

The article presents a monthly series of 10 top-ranked dividend growth stocks for further research and potential investment. The stocks are ranked based on quality scores, with tie-breaking metrics including dividend safety scores, credit ratings, and forward dividend yield. The top three stocks for this month are Visa, UnitedHealth, and Intercontinental Exchange. The article also provides key metrics and fair value estimates for each stock, and suggests that Tractor Supply Company passes all selection criteria for adding new positions to the author's DivGro portfolio.

10 Dividend Growth Stocks For July 2023

Apple

AbbVie

Arbor Realty Trust

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Becton, Dickinson and Co.

Blackrock Inc

Bristol-Myers

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AutoNation

Genuine Parts

PPG Industries

Snap-on

We have narrowed our search to five companies that are set to declare second-quarter earnings results next week. These are: GPC, ABT, AN, SNA, PPG.

5 Stocks to Buy Ahead of Q2 Earnings Next Week

LeMaitre Vascular

Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?

ABT vs. LMAT: Which Stock Should Value Investors Buy Now?

The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

Abbott will see a decline in sales given the forex headwinds and lower Covid-19-related testing demand.

Lower Testing Demand To Weigh On Abbott's Q2?

Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.

Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker

Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA battery Leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow or abnormal heart rhythms Approval comes on the heels of recent late-breaking clinical trial data showing that the AVEIR™ DR leadless pacemaker system is safe and effective at treating abnormal heart rhythms ABBOTT PARK, Ill., July 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.

Abbott Receives FDA Approval for World's First Dual-Chamber Leadless Pacemaker

Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.

Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems

I analyzed Abbott Laboratories, a healthcare company with a diversified portfolio that includes pharmaceuticals, diagnostic products, nutritional products, and medical devices. I believe Abbott has potential growth opportunities in diabetes care and cardiovascular diseases, with significant worldwide exposure allowing for increased sales in various markets. However, the company faces risks such as declining demand for Covid tests, competition, and a high valuation. In my opinion, shares of Abbott Laboratories are HOLD due to their high valuation. The shares would be attractive at a P/E ratio of 16-17 or a P/E ratio of 19 once the company returns to its growth path.

News for Abbott Labs Stock (ABT)